\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ information\\ provided\ \(0\)\
\-\ skin\\:\\ laser\\ tx\\ for\\ cosmesis\ \(0\)\
\-\ glaucoma\\:\\ close\\ follow\\-up\\ with\\ ophthalmology\\ with\\ goal\\ to\\ preserve\\ vision\\ and\\ control\\ iop\\ via\\ medications\\ and\\/or\\ surgery\\.\ \(0\)\
\-\ follow\\ up\\ imaging\\ to\\ track\\ disease\\ progression\\ in\\ presence\\ of\\ new\\ onset\\ of\\ sx\\,\\ seizures\\,\\ etc\\.\\.\ \(0\)\
\-\ focal\\ cortical\\ hypoplasia\\ of\\ the\\ left\\ occipital\\ lobe\\ seen\\ with\\ decreased\\ t2\\ signal\\ of\\ deep\\ white\\ matter\\,\\ along\\ with\\ increased\\ enhancement\\ of\\ overlying\\ leptomeninges\\ in\\ comparison\\ with\\ right\\.\\ \\ increased\\ signal\\ intensity\\ and\\ size\\ of\\ choroidal\\ plexus\\ noted\\ in\\ occipital\\ horn\\ of\\ left\\ ventricle\\ in\\ comparison\\ with\\ right\\.\\ \\ increased\\ pial\\ enhancement\\ of\\ left\\ parietal\\ lobe\\ in\\ comparison\\ with\\ right\\.\ \(0\)\
\-\ left\\ globe\\ enlargement\\ in\\ comparison\\ with\\ right\\ globe\\ \\(measured\\ at\\ 2\\.5\\ cm\\ vs\\ 2\\.0\\ cm\\ ap\\)\\.\ \(0\)\
\-\ sturge\\-weber\\ syndrome\ \(0\)\
\-\ findings\\ consistent\\ with\\ known\\ sturge\\-weber\\ syndrome\ \(0\)\
\-\ may\\ consider\\:\\ wyburn\\-mason\\ syndrome\\,\\ other\\ phakomatoses\ \(0\)\
\-\ 11\\ mo\\ female\\ with\\ known\\ syndrome\\ and\\ a\\ recent\\ diagnosis\\ of\\ glaucoma\\.\\ \\ no\\ history\\ of\\ developmental\\ delays\\ or\\ seizure\\ activity\\.\\ \\ procedure\\:\\ baseline\\ mri\\ of\\ brain\\ with\\ gadolinium\\ for\\ evaluation\\ of\\ disease\\ progression\\ in\\ future\\.\ \(0\)\
\-\ sturge\\-weber\\ syndrome\\ \\(sws\\)\\ or\\ encephalotrigeminal\\ angiomatosis\\ is\\ a\\ non\\-heritable\\ congenital\\ neurocutaneous\\ disorder\\ associated\\ with\\ vascular\\ malformations\\ of\\ the\\ leptomeninges\\,\\ choroid\\ of\\ the\\ eye\\,\\ and\\ skin\\ of\\ the\\ face\\ with\\ a\\ trigeminal\\ distribution\\.\\ \\ findings\\ are\\ ipsilateral\\ in\\ the\\ overwhelming\\ majority\\ of\\ patients\\,\\ but\\ can\\ also\\ be\\ bilateral\\.1\\ \\ pathogenesis\\ is\\ theorized\\ to\\ be\\ associated\\ with\\ inappropriate\\ control\\ of\\ normal\\ vascular\\ maturation\\ and\\ a\\ resultant\\ persistence\\ of\\ the\\ primitive\\ vascular\\ plexus2\\.\\ \\ diagnosis\\ is\\ based\\ on\\ demonstration\\ of\\ port\\-wine\\ stain\\ in\\ a\\ trigeminal\\ distribution\\ \\(not\\ pathognomonic\\)\\ and\\ leptomeningeal\\ angiomas\\,\\ although\\ variants\\ also\\ occur\\ with\\ an\\ absence\\ of\\ one\\ of\\ these\\ findings\\ in\\ the\\ presence\\ of\\ ocular\\ angiomas\\.3\\ \\ \ \(0\)\
\-\ the\\ predominant\\ ocular\\ feature\\ is\\ glaucoma\\,\\ with\\ a\\ congenital\\ presentation\\ seen\\ in\\ 50\\%\\ of\\ patients\\.\\ \\ early\\ presentation\\ in\\ the\\ newborn\\ begins\\ as\\ bupthalmos\\,\\ or\\ enlargement\\ of\\ the\\ globe\\.\\ \\ other\\ ocular\\ findings\\ include\\ choroidal\\ angiomas\\,\\ heterochromia\\ of\\ the\\ iris\\,\\ or\\ visual\\ field\\ defects\\,\\ such\\ as\\ homonymous\\ hemianopsia\\,\\ secondary\\ to\\ occipital\\ cortex\\ atrophy4\\.\ \(0\)\
\-\ neurologic\\ features\\ are\\ progressive\\ and\\ include\\ seizures\\,\\ focal\\ deficits\\,\\ and\\ mental\\ retardation\\,\\ although\\ it\\ is\\ possible\\ to\\ be\\ spared\\ neurologic\\ abnormalities\\.\\ \\ typically\\ children\\ will\\ have\\ no\\ developmental\\ delay\\ for\\ several\\ months\\ after\\ birth\\,\\ but\\ may\\ begin\\ to\\ slow\\ in\\ their\\ cognitive\\ development\\ as\\ the\\ disease\\ progresses\\.\\ \\ mechanism\\ for\\ this\\ progression\\ is\\ suggested\\ to\\ be\\ secondary\\ to\\ hypoxic\\ ischemia\\ in\\ tissues\\ that\\ failed\\ to\\ vascularize\\ appropriately\\ adjacent\\ to\\ the\\ leptomeningeal\\ angiomas\\.4\\ \\ seizures\\ are\\ often\\ the\\ presenting\\ symptom\\.\\ \\ their\\ frequency\\,\\ age\\ at\\ onset\\,\\ and\\ response\\ to\\ treatment\\ affect\\ prognosis4\\.\ \(0\)\
\-\ mri\\ reveals\\ the\\ angioma\\ as\\ a\\ hyperintense\\ enhancement\\ of\\ the\\ leptomeninges\\ on\\ t2\\-weighted\\ images\\ frequently\\ occipital\\ or\\ posterior\\ temporoparietal\\,\\ with\\ atrophy\\ of\\ adjacent\\ lobe\\.\\ \\ choroidal\\ angiomas\\ enhance\\ on\\ fat\\ suppressed\\ t1\\ imaging\\.3\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ leptomeninges\\:\\ 0\\.041495340137289505\ \(0\)\
\-\ sturge\\-weber\\:\\ 0\\.041495340137289505\ \(0\)\
\-\ glaucoma\\:\\ 0\\.039533612840871424\ \(0\)\
\-\ angiomas\\:\\ 0\\.039533612840871424\ \(0\)\
\-\ choroidal\\:\\ 0\\.036851982011767655\ \(0\)\
\-\ comparison\\:\\ 0\\.03651803344147414\ \(0\)\
\-\ occipital\\:\\ 0\\.032749114469521126\ \(0\)\
\-\ ocular\\:\\ 0\\.03189691333207462\ \(0\)\
\-\ globe\\:\\ 0\\.030587499931764517\ \(0\)\
\-\ progression\\:\\ 0\\.0261879069763778\ \(0\)\
\-\ syndrome\\:\\ 0\\.025091443292963464\ \(0\)\
\-\ seizures\\:\\ 0\\.022631549491563686\ \(0\)\
\-\ trigeminal\\:\\ 0\\.021970359429843003\ \(0\)\
\-\ leptomeningeal\\:\\ 0\\.020853588524366036\ \(0\)\
\-\ wyburn\\-mason\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ bilateral\\.1\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ plexus2\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ angiomas\\.3\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ bupthalmos\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ heterochromia\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ atrophy4\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ vascularize\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ angiomas\\.4\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ prognosis4\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ imaging\\.3\\:\\ 0\\.018101680542025666\ \(0\)\
\-\ vascular\\:\\ 0\\.01725956838556692\ \(0\)\
\-\ cosmesis\\:\\ 0\\.016678380376604834\ \(0\)\
\-\ sws\\:\\ 0\\.016678380376604834\ \(0\)\
\-\ encephalotrigeminal\\:\\ 0\\.016678380376604834\ \(0\)\
\-\ developmental\\:\\ 0\\.016309368942537608\ \(0\)\
\-\ control\\:\\ 0\\.015998100608371143\ \(0\)\
\-\ non\\-heritable\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ theorized\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ port\\-wine\\:\\ 0\\.015845803152563426\ \(0\)\
\-\ distribution\\:\\ 0\\.01579345020283572\ \(0\)\
\-\ their\\:\\ 0\\.015360758146746084\ \(0\)\
\-\ findings\\:\\ 0\\.01493911240895244\ \(0\)\
\-\ phakomatoses\\:\\ 0\\.014796879900477204\ \(0\)\
\-\ iris\\:\\ 0\\.014796879900477204\ \(0\)\
\-\ temporoparietal\\:\\ 0\\.014796879900477204\ \(0\)\
\-\ neurologic\\:\\ 0\\.014655007604952823\ \(0\)\
\-\ delays\\:\\ 0\\.014422502987142594\ \(0\)\
\-\ neurocutaneous\\:\\ 0\\.014422502987142594\ \(0\)\
\-\ overwhelming\\:\\ 0\\.014422502987142594\ \(0\)\
\-\ lobe\\:\\ 0\\.014164221855791791\ \(0\)\
\-\ enhancement\\:\\ 0\\.014109787060306177\ \(0\)\
\-\ iop\\:\\ 0\\.014105971817066089\ \(0\)\
\-\ inappropriate\\:\\ 0\\.014105971817066089\ \(0\)\
\-\ maturation\\:\\ 0\\.014105971817066089\ \(0\)\
\-\ enlargement\\:\\ 0\\.01392430557078068\ \(0\)\
\-\ angiomatosis\\:\\ 0\\.013831780045763168\ \(0\)\
\-\ preserve\\:\\ 0\\.013589925763101187\ \(0\)\
\-\ pial\\:\\ 0\\.013589925763101187\ \(0\)\
\-\ homonymous\\:\\ 0\\.013589925763101187\ \(0\)\
\-\ skin\\:\\ 0\\.013478968933219622\ \(0\)\
\-\ sx\\:\\ 0\\.012999202821721761\ \(0\)\
\-\ increased\\:\\ 0\\.0128777296620102\ \(0\)\
\-\ variants\\:\\ 0\\.012834844079065629\ \(0\)\
\-\ congenital\\:\\ 0\\.012834328417422743\ \(0\)\
\-\ presence\\:\\ 0\\.012738339295511825\ \(0\)\
\-\ laser\\:\\ 0\\.012408479880342334\ \(0\)\
\-\ hypoxic\\:\\ 0\\.012408479880342334\ \(0\)\
\-\ in\\:\\ 0\\.012114088751465234\ \(0\)\
\-\ presentation\\:\\ 0\\.012087887615979806\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.012055604609445705\ \(0\)\
\-\ spared\\:\\ 0\\.011950279569635538\ \(0\)\
\-\ although\\:\\ 0\\.011851865628651351\ \(0\)\
\-\ ophthalmology\\:\\ 0\\.01185009442760385\ \(0\)\
\-\ retardation\\:\\ 0\\.01185009442760385\ \(0\)\
\-\ suppressed\\:\\ 0\\.01185009442760385\ \(0\)\
\-\ hemianopsia\\:\\ 0\\.011754570781536309\ \(0\)\
\-\ progresses\\:\\ 0\\.011754570781536309\ \(0\)\
\-\ \\,\\:\\ 0\\.011673329313887136\ \(0\)\
\-\ \\.\\.\\:\\ 0\\.011663294061678334\ \(0\)\
\-\ persistence\\:\\ 0\\.011663294061678334\ \(0\)\
\-\ begin\\:\\ 0\\.011663294061678334\ \(0\)\
\-\ cognitive\\:\\ 0\\.011663294061678334\ \(0\)\
\-\ 2\\.0\\:\\ 0\\.01157590265630093\ \(0\)\
\-\ feature\\:\\ 0\\.01157590265630093\ \(0\)\
\-\ track\\:\\ 0\\.011492079258928742\ \(0\)\
\-\ goal\\:\\ 0\\.011411543913644797\ \(0\)\
\-\ primitive\\:\\ 0\\.011411543913644797\ \(0\)\
\-\ demonstration\\:\\ 0\\.01133404837363895\ \(0\)\
\-\ predominant\\:\\ 0\\.01133404837363895\ \(0\)\
\-\ known\\:\\ 0\\.011104932585067022\ \(0\)\
\-\ adjacent\\:\\ 0\\.011095836731557566\ \(0\)\
\-\ onset\\:\\ 0\\.011077705239939015\ \(0\)\
\-\ mo\\:\\ 0\\.011050372113924747\ \(0\)\
\-\ begins\\:\\ 0\\.010921993557494902\ \(0\)\
\-\ appropriately\\:\\ 0\\.010921993557494902\ \(0\)\
\-\ tx\\:\\ 0\\.010860693838501719\ \(0\)\
\-\ be\\:\\ 0\\.010823463846767386\ \(0\)\
\-\ stain\\:\\ 0\\.010801171175517628\ \(0\)\
\-\ as\\:\\ 0\\.010616653025824459\ \(0\)\
\-\ baseline\\:\\ 0\\.010378477019040936\ \(0\)\
\-\ resultant\\:\\ 0\\.010285125121552729\ \(0\)\
\-\ angioma\\:\\ 0\\.010285125121552729\ \(0\)\
\-\ or\\:\\ 0\\.010282574424678722\ \(0\)\
\-\ ipsilateral\\:\\ 0\\.010110263092106513\ \(0\)\
\-\ affect\\:\\ 0\\.010110263092106513\ \(0\)\
\-\ focal\\:\\ 0\\.010022561002621775\ \(0\)\
\-\ symptom\\:\\ 0\\.009949130411528494\ \(0\)\
\-\ include\\:\\ 0\\.009844572846120274\ \(0\)\
\-\ secondary\\:\\ 0\\.009811211361432474\ \(0\)\
\-\ malformations\\:\\ 0\\.009799727219983467\ \(0\)\
\-\ failed\\:\\ 0\\.009799727219983467\ \(0\)\
\-\ future\\:\\ 0\\.009728913716757246\ \(0\)\
\-\ to\\:\\ 0\\.009646302244092093\ \(0\)\
\-\ information\\:\\ 0\\.00956187954950067\ \(0\)\
\-\ hypoplasia\\:\\ 0\\.00956187954950067\ \(0\)\
\-\ newborn\\:\\ 0\\.00956187954950067\ \(0\)\
\-\ horn\\:\\ 0\\.009530043437517169\ \(0\)\
\-\ measured\\:\\ 0\\.009530043437517169\ \(0\)\
\-\ consider\\:\\ 0\\.009530043437517169\ \(0\)\
\-\ etc\\:\\ 0\\.00949869339207407\ \(0\)\
\-\ 2\\.5\\:\\ 0\\.00949869339207407\ \(0\)\
\-\ pathognomonic\\:\\ 0\\.00949869339207407\ \(0\)\
\-\ slow\\:\\ 0\\.00949869339207407\ \(0\)\
\-\ cm\\:\\ 0\\.009412550791856204\ \(0\)\
\-\ \\:\\:\\ 0\\.0092835713839069\ \(0\)\
\-\ frequency\\:\\ 0\\.009263764539553035\ \(0\)\
\-\ signal\\:\\ 0\\.009252871992906688\ \(0\)\
\-\ patients\\:\\ 0\\.009082441886513453\ \(0\)\
\-\ atrophy\\:\\ 0\\.009052975722181202\ \(0\)\
\-\ mechanism\\:\\ 0\\.009028085864825256\ \(0\)\
\-\ field\\:\\ 0\\.009003494096762186\ \(0\)\
\-\ choroid\\:\\ 0\\.008955176853620104\ \(0\)\
\-\ suggested\\:\\ 0\\.008931437998587094\ \(0\)\
\-\ t2\\-weighted\\:\\ 0\\.008884768078509978\ \(0\)\
\-\ response\\:\\ 0\\.008794494724462509\ \(0\)\
\-\ delay\\:\\ 0\\.008708023501977651\ \(0\)\
\-\ majority\\:\\ 0\\.008625047037218149\ \(0\)\
\-\ face\\:\\ 0\\.00860481644903948\ \(0\)\
\-\ disease\\:\\ 0\\.008604132697427335\ \(0\)\
\-\ close\\:\\ 0\\.008564943582803134\ \(0\)\
\-\ plexus\\:\\ 0\\.008525830246107662\ \(0\)\
\-\ enhance\\:\\ 0\\.008487448042797286\ \(0\)\
\-\ birth\\:\\ 0\\.008431187315511632\ \(0\)\
\-\ gadolinium\\:\\ 0\\.008323089300141154\ \(0\)\
\-\ associated\\:\\ 0\\.008281160418512123\ \(0\)\
\-\ mental\\:\\ 0\\.008187278617380282\ \(0\)\
\-\ ischemia\\:\\ 0\\.008154684471268804\ \(0\)\
\-\ vision\\:\\ 0\\.008106743272096336\ \(0\)\
\-\ other\\:\\ 0\\.008088864676396093\ \(0\)\
\-\ mri\\:\\ 0\\.008062734517103163\ \(0\)\
\-\ defects\\:\\ 0\\.00805989588448613\ \(0\)\
\-\ diagnosis\\:\\ 0\\.008058395608954497\ \(0\)\
\-\ 11\\:\\ 0\\.00802924773209049\ \(0\)\
\-\ deficits\\:\\ 0\\.00802924773209049\ \(0\)\
\-\ visual\\:\\ 0\\.007954570844675964\ \(0\)\
\-\ overlying\\:\\ 0\\.007939955921125934\ \(0\)\
\-\ disorder\\:\\ 0\\.00788251474650087\ \(0\)\
\-\ left\\:\\ 0\\.007853020692179998\ \(0\)\
\-\ medications\\:\\ 0\\.007826636792651005\ \(0\)\
\-\ seizure\\:\\ 0\\.007758862056576734\ \(0\)\
\-\ may\\:\\ 0\\.007697447100197634\ \(0\)\
\-\ development\\:\\ 0\\.007642234544475844\ \(0\)\
\-\ frequently\\:\\ 0\\.007604785699404425\ \(0\)\
\-\ children\\:\\ 0\\.007580193931341354\ \(0\)\
\-\ provided\\:\\ 0\\.007568007616105595\ \(0\)\
\-\ via\\:\\ 0\\.007531876688199272\ \(0\)\
\-\ cortex\\:\\ 0\\.0075081378331662615\ \(0\)\
\-\ parietal\\:\\ 0\\.007496370533969167\ \(0\)\
\-\ but\\:\\ 0\\.007484613145928286\ \(0\)\
\-\ and\\/or\\:\\ 0\\.007415835188685221\ \(0\)\
\-\ right\\:\\ 0\\.007405599253473649\ \(0\)\
\-\ features\\:\\ 0\\.007404583718942664\ \(0\)\
\-\ eye\\:\\ 0\\.0073601844088540275\ \(0\)\
\-\ procedure\\:\\ 0\\.007349232979746508\ \(0\)\
\-\ absence\\:\\ 0\\.0072953351849314434\ \(0\)\
\-\ hyperintense\\:\\ 0\\.007284723336556818\ \(0\)\
\-\ tissues\\:\\ 0\\.007201746871797317\ \(0\)\
\-\ are\\:\\ 0\\.007175814409833276\ \(0\)\
\-\ presenting\\:\\ 0\\.007151539282753859\ \(0\)\
\-\ deep\\:\\ 0\\.007102530080686829\ \(0\)\
\-\ progressive\\:\\ 0\\.00693519325470904\ \(0\)\
\-\ seen\\:\\ 0\\.006934815667629118\ \(0\)\
\-\ is\\:\\ 0\\.006927607125889843\ \(0\)\
\-\ also\\:\\ 0\\.006918355620821977\ \(0\)\
\-\ matter\\:\\ 0\\.00690858310143901\ \(0\)\
\-\ vs\\:\\ 0\\.00690858310143901\ \(0\)\
\-\ reveals\\:\\ 0\\.006864985113542142\ \(0\)\
\-\ based\\:\\ 0\\.006691355980014293\ \(0\)\
\-\ 50\\:\\ 0\\.006675560609124856\ \(0\)\
\-\ activity\\:\\ 0\\.0065832579646438166\ \(0\)\
\-\ occur\\:\\ 0\\.0065832579646438166\ \(0\)\
\-\ ventricle\\:\\ 0\\.006575750138764739\ \(0\)\
\-\ of\\:\\ 0\\.006459142960052747\ \(0\)\
\-\ abnormalities\\:\\ 0\\.006445101892604141\ \(0\)\
\-\ ap\\:\\ 0\\.0064171642087113715\ \(0\)\
\-\ early\\:\\ 0\\.0064171642087113715\ \(0\)\
\-\ cortical\\:\\ 0\\.0063964575987183\ \(0\)\
\-\ intensity\\:\\ 0\\.006342239581887682\ \(0\)\
\-\ typically\\:\\ 0\\.006193892750525611\ \(0\)\
\-\ new\\:\\ 0\\.006114554367146937\ \(0\)\
\-\ for\\:\\ 0\\.005988567955997661\ \(0\)\
\-\ possible\\:\\ 0\\.005909614412492961\ \(0\)\
\-\ recent\\:\\ 0\\.005898807081806565\ \(0\)\
\-\ size\\:\\ 0\\.005882701994617601\ \(0\)\
\-\ white\\:\\ 0\\.005819515837191001\ \(0\)\
\-\ along\\:\\ 0\\.005798878597245413\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.005708494848956349\ \(0\)\
\-\ a\\:\\ 0\\.0057006131678238375\ \(0\)\
\-\ several\\:\\ 0\\.005640847711955621\ \(0\)\
\-\ often\\:\\ 0\\.005598508313182038\ \(0\)\
\-\ follow\\:\\ 0\\.005575358258616908\ \(0\)\
\-\ t1\\:\\ 0\\.005561592476846497\ \(0\)\
\-\ will\\:\\ 0\\.00548969408291405\ \(0\)\
\-\ such\\:\\ 0\\.005485282936018177\ \(0\)\
\-\ age\\:\\ 0\\.005340678286538617\ \(0\)\
\-\ fat\\:\\ 0\\.005336575611666598\ \(0\)\
\-\ no\\:\\ 0\\.005300477314397137\ \(0\)\
\-\ brain\\:\\ 0\\.005279982594050846\ \(0\)\
\-\ decreased\\:\\ 0\\.005217158937832771\ \(0\)\
\-\ evaluation\\:\\ 0\\.005096999580753199\ \(0\)\
\-\ t2\\:\\ 0\\.004966301373204009\ \(0\)\
\-\ months\\:\\ 0\\.004792487258090487\ \(0\)\
\-\ one\\:\\ 0\\.004755095242937667\ \(0\)\
\-\ at\\:\\ 0\\.004754674138938945\ \(0\)\
\-\ up\\:\\ 0\\.004718371973417296\ \(0\)\
\-\ these\\:\\ 0\\.004566416205252238\ \(0\)\
\-\ the\\:\\ 0\\.004542070955355262\ \(0\)\
\-\ on\\:\\ 0\\.0044592875505057175\ \(0\)\
\-\ \\(\\:\\ 0\\.004449866896779429\ \(0\)\
\-\ \\)\\:\\ 0\\.00439550939700188\ \(0\)\
\-\ consistent\\:\\ 0\\.00430246051094703\ \(0\)\
\-\ surgery\\:\\ 0\\.004260778366242865\ \(0\)\
\-\ noted\\:\\ 0\\.004158975746309228\ \(0\)\
\-\ imaging\\:\\ 0\\.004111034547136762\ \(0\)\
\-\ \\%\\:\\ 0\\.004093061670115005\ \(0\)\
\-\ with\\:\\ 0\\.004084334688969456\ \(0\)\
\-\ posterior\\:\\ 0\\.0040444323381980465\ \(0\)\
\-\ can\\:\\ 0\\.003979922695008357\ \(0\)\
\-\ it\\:\\ 0\\.003944247196166359\ \(0\)\
\-\ have\\:\\ 0\\.0037996675120433097\ \(0\)\
\-\ after\\:\\ 0\\.00363039261316058\ \(0\)\
\-\ female\\:\\ 0\\.0036073106189893917\ \(0\)\
\-\ treatment\\:\\ 0\\.0035515748657102405\ \(0\)\
\-\ images\\:\\ 0\\.0033660449526680784\ \(0\)\
\-\ and\\:\\ 0\\.0033266551367350434\ \(0\)\
\-\ that\\:\\ 0\\.00303076124960744\ \(0\)\
\-\ normal\\:\\ 0\\.0027507442599570865\ \(0\)\
\-\ not\\:\\ 0\\.0025355619542955553\ \(0\)\
\-\ an\\:\\ 0\\.0024264165591062216\ \(0\)\
\-\ history\\:\\ 0\\.002423438475784566\ \(0\)\
\-\ this\\:\\ 0\\.00197358770701054\ \(0\)\
\-\ \\.\\:\\ 0\\.0013120978434337431\ \(0\)\
